Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly Whomps Novo Nordisk
Tirzepatide Tops Semaglutide for Weight Loss in Head-to-Head Trial, Eli Lilly Says
Adults on the obesity medication tirzepatide (Zepbound) lost more weight on average than those on semaglutide (Wegovy) in a head-to-head trial of the two injectables, Eli Lilly announced on Wednesday.
Eli Lilly's Zepbound Tops Novo Nordisk's Wegovy in Weight-Loss Trial
Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, according results of the study released Wednesday.
Eli Lilly's GLP-1 outdoes Novo Nordisk's in trial
Adults taking Eli Lilly's Zepbound lost 47% more weight on average than those on Novo Nordisk's Wegovy, Lilly reported from the first head-to-head trial comparing the two blockbuster GLP-1 obesity drugs.
Seeking Alpha on MSN
44m
Lilly planning $3B expansion of Wisconsin plant to boost production
Eli
Lilly
(NYSE:LLY) plans to boost production of its popular ...
Lilly
has faced soaring demand for its drug ...
3h
Eli Lilly to spend $3 billion, add 750 employees in Kenosha County expansion
Drugmaker Eli Lilly and Co. will invest $3 billion and add 750 employees in Kenosha County as the company expands a plant it ...
Yahoo Finance
8h
The Weight Loss Drug Race Heats Up: Eli Lilly's Zepbound Outperforms Wegovy in Weight Loss Trials
Eli
Lilly
(NYSE:LLY) has been making headlines recently with its weight-loss drug Zepbound (
tirzepatide
).
Eli
Lilly
...
1d
on MSN
Eli Lilly Just Got a Bundle of Good News: Time to Buy?
One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...
MM&M
1h
Eli Lilly CEO: More than 20% of Americans will eventually be on GLP-1s
DealBook Summit, Lilly CEO David Ricks said GLP-1 drugs have the potential to treat more than obesity — including heart disease and substance use disorders.
STAT
23h
U.K. to restrict Eli Lilly’s obesity drug to patients with greatest need
The U.K. will soon offer Eli Lilly's Mounjaro for people with obesity — but only to a small share of those medically eligible ...
7d
on MSN
Down More Than 20% From Its High, Is Now the Time to Buy Eli Lilly Stock?
Eli Lilly ( LLY 0.91%) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Zepbound
Wegovy
Glucagon-like peptide-1
Feedback